ArticleCancer chemotherapy and pharmacology2023

A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.

John F Marcelletti et al.PubMed ↗Publisher ↗

No numbers read from the abstract.